Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04807660
Recruiting Observational

Bacteriological Evaluation of Children With Otorrhea

NCT04807660 · tracked via the Priya Life Science France tracker
Sponsor
Association Clinique Thérapeutique Infantile du val de Marne
Phase
Observational
Started
2015-10-01
Last updated
2026-03-19

Condition(s) studied

Otorrhea

Investigational drug(s) / intervention(s)

middle ear fluid sample for bacterial analysis (conventional microbiology analysis)

middle ear fluid sample for bacterial analysis (conventional microbiology analysis): A middle ear fluid sample will be collected from each enrolled child for the third analysis procedure.

Study summary

After pneumococcal conjugate vaccine implementation, the number of acute otitis media (AOM) episodes has decreased, but AOM still remains among the most common diagnoses in childhood. From 2% to 17% of cases of AOM feature spontaneous perforation of the tympanic membrane (SPTM). The aim of this study was to describe the bacteriological causes of SPTM several years after PCV13 implementation, in 2010.

Eligibility

Sex
ALL
Min age
3 Months
Max age
15 Years
Healthy volunteers
No
Inclusion Criteria: * children from 3 months to 15 years old * with otorrhea * signed parents consent Exclusion Criteria: * children under 3 months * children \> 15 years old

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
ACTIV Créteil France Recruiting

More Association Clinique Thérapeutique Infantile du val de Marne trials in France

Pediatric and Ambulatory Research in Infectious Diseases Recruiting
National, Non Interventional Study of Invasive Pneumococcal Disease in Children and Newborns Recruiting
Pediatric Pertussis in Ambulatory Settings Recruiting
CommunautAry Pediatric bacteRial Infection in Intensive CarE Unit Recruiting
Nasopharyngeal Carriage of S. Pneumoniae Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04807660 on ClinicalTrials.gov ↗ ← All trials in France